BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36053276)

  • 1. Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia.
    Liu Y; Li Q; Alikarami F; Barrett DR; Mahdavi L; Li H; Tang S; Khan TA; Michino M; Hill C; Song L; Yang L; Li Y; Pokharel SP; Stamford AW; Liverton N; Renzetti LM; Taylor S; Watt GF; Ladduwahetty T; Kargman S; Meinke PT; Foley MA; Shi J; Li H; Carroll M; Chen CW; Gardini A; Maillard I; Huggins DJ; Bernt KM; Wan L
    Cancer Discov; 2022 Nov; 12(11):2684-2709. PubMed ID: 36053276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia.
    Hu H; Saha N; Yang Y; Ahmad E; Lachowski L; Shrestha U; Premkumar V; Ropa J; Chen L; Teahan B; Grigsby S; Marschalek R; Nikolovska-Coleska Z; Muntean AG
    Leukemia; 2023 Jan; 37(1):190-201. PubMed ID: 36435883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.
    Wan L; Wen H; Li Y; Lyu J; Xi Y; Hoshii T; Joseph JK; Wang X; Loh YE; Erb MA; Souza AL; Bradner JE; Shen L; Li W; Li H; Allis CD; Armstrong SA; Shi X
    Nature; 2017 Mar; 543(7644):265-269. PubMed ID: 28241141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcription control by the ENL YEATS domain in acute leukaemia.
    Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
    Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The YEATS domain epigenetic reader proteins ENL and AF9 and their therapeutic value in leukemia.
    Hu H; Muntean AG
    Exp Hematol; 2023 Aug; 124():15-21. PubMed ID: 37295550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable
    Michino M; Khan TA; Miller MW; Fukase Y; Vendome J; Adura C; Glickman JF; Liu Y; Wan L; Allis CD; Stamford AW; Meinke PT; Renzetti LM; Kargman S; Liverton NJ; Huggins DJ
    ACS Med Chem Lett; 2024 Apr; 15(4):524-532. PubMed ID: 38628784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9.
    Christott T; Bennett J; Coxon C; Monteiro O; Giroud C; Beke V; Felce SL; Gamble V; Gileadi C; Poda G; Al-Awar R; Farnie G; Fedorov O
    SLAS Discov; 2019 Feb; 24(2):133-141. PubMed ID: 30359161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.
    Zhou J; Ng Y; Chng WJ
    Cell Mol Life Sci; 2018 Nov; 75(21):3931-3941. PubMed ID: 30066088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis of novel benzimidazole derivatives as ENL inhibitors suppressing leukemia cells viability via downregulating the expression of MYC.
    Guo S; Jia T; Xu X; Yang F; Xiao S; Hou Z; Xu H; Ma S; Liu X; Luo C; Jiang H; Chen H; Chen S
    Eur J Med Chem; 2023 Feb; 248():115093. PubMed ID: 36645983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
    Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
    Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin.
    Zeisig DT; Bittner CB; Zeisig BB; García-Cuéllar MP; Hess JL; Slany RK
    Oncogene; 2005 Aug; 24(35):5525-32. PubMed ID: 15856011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
    Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
    Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
    Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
    Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
    Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
    Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficiency of murine MLL-ENL-driven leukemia initiation changes with age and peaks during neonatal development.
    Okeyo-Owuor T; Li Y; Patel RM; Yang W; Casey EB; Cluster AS; Porter SN; Bryder D; Magee JA
    Blood Adv; 2019 Aug; 3(15):2388-2399. PubMed ID: 31405949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
    Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
    Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
    Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
    Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Selective Small-Molecule Inhibitors for the ENL YEATS Domain.
    Ma XR; Xu L; Xu S; Klein BJ; Wang H; Das S; Li K; Yang KS; Sohail S; Chapman A; Kutateladze TG; Shi X; Liu WR; Wen H
    J Med Chem; 2021 Aug; 64(15):10997-11013. PubMed ID: 34279931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.